Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety and Immunogenicity of New Formulations of GlaxoSmithKline Biologicals' DTPa-HBV-IPV/Hib Vaccine (GSK217744) in Primary Infant Vaccination

NCT01248884 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT01248884
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01248884 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety and Immunogenicity of New Formulations of GlaxoSmithKline Biologicals' DTPa-HBV-IPV/Hib Vaccine (GSK217744) in Primary Infant Vaccination
Lead sponsor
GlaxoSmithKline
Phase
Phase 2
Overall status
Completed
Start date
December 9, 2010
Completion date
January 5, 2012
Enrollment
721 (actual)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

acellular pertussis, diphtheria, haemophilus influenzae type b, hepatitis b, poliomyelitis, tetanus